Editas Medicine (EDIT) Tops Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Editas Medicine (EDIT) Tops Q2 EPS by 6c

Editas Medicine Announces Second Quarter 2017 Results and Update

August 9, 2017 4:03 PM EDT

Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials

Achieved research milestone in Juno Therapeutics, Inc., collaboration

CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the second quarter ended June 30, 2017, and provided an update on recent achievements and upcoming events.

This quarter, we made critical progress in advancing our LCA10 product candidate toward the clinic, as well as in our broader pipeline, said Katrine Bosley, President and Chief Executive... More